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Introduction
Parkinson's disease (PD) is a common movement disorder and, after Alzheimer's disease, the most frequent progressive neurodegenerative disorder (Shastry, 2001) . It is characterized by a loss of dopaminergic neurons and debilitating motorand non-motor symptoms (Sprenger and Poewe, 2013) . No disease-modifying or preventive therapies exist, and current therapeutics only alleviate symptoms by counteracting dopamine loss (Poewe, 2009) . However, the benefits of these treatments are limited by a gradual loss of efficacy and long-term adverse effects (Jankovic and Aguilar, 2008) . One of the recently proposed non-dopaminergic drug targets is RGS4, a GTPase accelerating protein for specific G-protein coupled receptors (De Vries et al., 2000) . Increased RGS4 activity following disease-related dopamine loss has been suggested to lead to PD-associated dysfunction of neuronal projections to the Globus Pallidus and Substantia Nigra (SN) (Di Marzo et al., 2000; Lerner and Kreitzer, 2012) . A first indication that RGS4 may be a target for PD was based on the observation that mice lacking the Rgs4 gene (Rgs4 -/-mice) were functionally less impaired than wild type controls after 6-OHDA lesioning of their nigrostriatal pathway (Lerner and Kreitzer, 2012) . To investigate if RGS4 inhibition provides protection against injury-induced loss of nigral dopaminergic neuron structure and function, focusing on the evaluation of RGS4 as a target for PD, an aspect that has not been investigated in-depth previously, we measured behavioral and neuropathological effects of intracerebral 6-OHDA administration in Rgs4 -/-mice and their littermate wild type controls (Grillet et al., 2005) . Since mice lacking both alleles of a gene can compensate for this lack and do not always have the same phenotype or response to injury as heterozygotes (Klamer et al., 2005) , we also analyzed partially deficient RGS4 mice (Rgs4
). We found that motor function was significantly impaired by 6-OHDA in both Rgs4 -/-and Rgs4 +/-mice, with
Rgs4
-/-mice even showing motor deficiencies in tests that showed no or only slight impairment of Rgs4 +/+ wild type controls. We also observed that neither TH positive fibers in the striatum, nor TH-positive neurons in the SN were protected M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
against 6-OHDA induced injury. Our results contrast with those of a previous study (Lerner and Kreitzer, 2012) and indicate that Rgs4 gene deletion does not always protect against toxin induced nigral neuron dysfunction and injury in mice.
Methods
All experiments were approved by the institutional Animal Experimentation Ethics Committee, and by appropriate government agencies. Heterozygote Rgs4 (Rgs4 +/-) mice were purchased from Jackson (#005833;
https://www.jax.org/strain/005833) and bred with C57BL/6J wild type mice from the same vendor to obtain study cohorts (see Suppl. Mat., Materials and Methods section, for details on genotyping). Mice were used at 12-18 weeks of age (equal numbers of males and females), and euthanized after the in-life procedures. Standard protocols were used according to the reference publications for stereotactical unilateral intrastriatal 6-OHDA injections (Bagga et al., 2015) , motor behavior measurements (cylinder test (Glajch et al., 2012) , pole test (Matsuura et al., 1997) , grip strength (Ferguson et al., 2015) ), tyrosine-hydroxylase (TH) immunostaining and quantitative image analysis of striatal and nigral TH positive neurons (Masliah et al., 2000) , except for minor modifications as detailed in the Supplemental Material. The morphometric quantitation of TH-positive nigral neurons was validated by stereological assessment on a separate set of tissues (see Suppl. Mat. and Suppl Fig. 2 ). For statistical evaluation, all variables were first tested for normality (Shapiro-
Since for each type of measurement, the normality assumption was rejected at least once, the non-parametric Kruskal-Wallis test was used for multiple comparisons, followed by the MannWhitney test for pairwise group comparisons. Control groups were either wild type mice prior surgery or the wild type mice after injection with vehicle. P-values below 5% were considered significant.
Results
We observed no gross neurological, developmental, or organ deficiencies in heterozygous (Rgs4
) mice compared to their wild type littermate controls (Rgs4
). The segregation of genotypes in the study cohorts was Mendelian. Weights of mice in all three genotypes were similar (Supp. Fig. 1 A, B) . In three different behavioral motor assessments (pole, grip strength, and cylinder tests) Rgs4 -/-and Rgs4 +/-mice showed no significantly different performance in comparison to Rgs4 +/+ controls (Suppl. Fig. 1, A-F) . The integrity of their nigrostriatal pathway, measured by TH immunostaining, was also similar to that of their Rgs4 +/+ littermates (Supp. Fig. 1G ). This allowed us to use these mice to study the effects of RGS4-deficiency on experimental PD-related disease outcomes. After determining that a dose of 2 µg 6-OHDA induced limited motor deficits (significant in one out of four tests, the cylinder test), and unilateral TH neuron loss of approximately 50% in wild type mice (Fig. 1, 2) , we observed that neither Rgs4 +/-nor Rgs4 -/-mice were protected against 6-OHDA induced motor deficits (Fig. 1) . Remarkably, we noticed that lesioned Rgs4 -/-, but not Rgs4
or Rgs4 +/+ mice, were significantly impaired in a measure of motor coordination (time to turn at top of the pole, Fig. 1 A) , while also showing a tendency toward impairment in another such measure (time to climb down the pole, Fig. 1 B) .
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Lesioned Rsg4 -/-mice also showed a worse outcome in muscle coordination (grip strength, Fig. 1 C) . Lesioned mice of all three genotypes were similarly impaired in the cylinder test. (Fig. 1 D) . We also found that 6-OHDA administration induced a similar loss of striatal positive TH fibers (Fig. 2 A, B) and of nigral TH-positive neurons (Fig. 2 A, C) in mice of all genotypes in their ipsilateral brain sides. Our results indicate that loss of one or both Rgs4 alleles in mice does not protect against PD toxin-induced dysfunction and injury.
Discussion
RGS4 is considered a potential non-dopaminergic drug target for PD. Rgs4
-/-mice were reported to be functionally less impaired than wild type controls after 6-OHDA administration (Lerner and Kreitzer, 2012) , Rgs4 expression inhibition was shown to reduce L-Dopa-induced dyskinesias in rats (Ko et al., 2014) , and inhibition of RGS4 activity was shown to counteract parkinsonism-related bradykinesia induced by the toxin raclopride in mice (Blazer et al., 2015) . Here however, using a battery of behavioral and histological measurements on the 6-OHDA mouse model of parkinsonism, we fail to observe a protective effect of lowered or absent Rgs4 expression. Moreover, we observe that 6-OHDA induced impairments in some motor tests in the complete absence of Rgs4 expression but not in its presence. Our findings show that reducing RGS4 is not protective in a toxin model of PD, and even suggest that extended treatment with an RGS4
inhibitor may lead to adverse effects, in particular in the presence of an already existing pathology. These observations are important because, in drug discovery research, multiple assessments are required to enable a robust target validation. We conclude that, while it is still possible that RGS4 inhibition may be useful for the management of PDrelated brady-or dyskinesias (Blazer et al., 2015; Ko et al., 2014) , or for other neurological disease indications (Gu et al., 2007) , for actual neuroprotection in PD, it should be approached with caution. Cylinde test. The bars represent the group medians +/-the interquartile ranges (data was not normally distributed).
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